triiodothyronine

[키워드] (therapeutic dose) 1:1 48 hour 48 hours Acute myocardial infarction addition Administered administration adopted allocation sequence Alpha Analysis blinded Blinding Caregivers clinical evidence collected comparator conserved copy Corticosteroid COVID-19 COVID-19 infected patient COVID-19 infection CRF criterion Critical Critical illness Critically ill Critically ill patient critically ill patients database defined detect Device diagnosed dissemination dosage dose double-blind drug Drug administration ECMO effective Efficacy and safety element enrolled Estimated EudraCT excluded extubation favorable effect female patient Final final analysis Follow-up followed by Germany Greece group hypoxia hypoxic condition hypoxic conditions ICU Identifier Ill illness immune system include increased mortality indicate information infusion initiation of treatment injection intensive care unit interim analysis investigator IWRS less Life expectancy maintenance dose MAPK mechanical respiratory mechanical ventilation multi-organ dysfunction number objective outcome participant Patient performed pharmacological treatment Placebo placebo controlled trial Pregnancy Primary outcome protocol Pulmonary infection randomisation randomised randomised controlled trial randomization Randomized recruited recruitment reveal Sample size Sepsis severe systemic disease signaling pathways solution Sponsor status study groups Study protocol subject Support systemic disease therapeutic therapeutic dose Thyroid thyroid hormone tissue trauma Treatment treatment allocation Trial Trial registration triiodothyronine unblinding university university hospital ventilatory support Version Viral viral infection Viral load website with COVID-19
[DOI] 10.1186/s13063-020-04474-0 PMC 바로가기 [Article Type] Letter